Latest Drug-eluting stent Stories

InspireMD To Participate In Benchmark Investor Conference On May 30th

2013-05-24 08:23:18

BOSTON and TEL AVIV, Israel, May 24, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo, the Company's President and Chief Executive Officer, and Craig Shore, the Company's Chief Financial Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on Thursday May 30, 2013 at The Pfister Hotel, 424 East Wisconsin Ave., Milwaukee, WI. The...

InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group

2013-05-23 08:26:36

Company to Host Conference Call Today at 8:00am ET, 2:00pm CET PARIS, May 23, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial...

Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013

2013-05-23 04:21:45

Prospective, Multi-Center, Double-Blinded Study Confirms Prior Results in evaluating Volcano's iFR® (Instant Wave-Free Ratio(TM)) Software Modality in a Large, Real-World Population SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary results from the ADVISE...

Boston Scientific Promus PREMIER(TM) And SYNERGY(TM) Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data

2013-05-22 08:29:49

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial...

Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

2013-05-21 08:28:47

- XIENCE Xpedition(TM) 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition(TM) 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and...

Delayed Healing of Coronary Artery Following Implantation of Drug Eluting Stents, Increasing Risk of Thrombosis, is a Top Concern of Interventional Cardiologists, International Survey Shows

2013-05-21 04:20:47

PARIS, May 21, 2013 /PRNewswire/ -- The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris. In the online survey of 141 interventional cardiologists in Belgium, China, Denmark, Germany, Italy, Malaysia, The Netherlands, Singapore and the United Kingdom,...

Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device

2013-05-20 23:19:09

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients

2013-05-20 04:20:50

Results of Randomized JACK-EPC Trial Published in Minerva Cardioangiologica HONG KONG, May 20, 2013 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva...

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

2013-05-17 04:20:42

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER((TM))...

InspireMD to Announce Six-Month Results from the MGuard(TM) Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

2013-05-16 20:22:40

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...